Abstract 4401
Background
In Feb 2015, palbociclib plus letrozole (P+L) became the first cyclin-dependent-kinase 4/6 inhibitor approved for mBC/aBC in the US. Until now, long-term outcomes studies have included a limited number of patients receiving P+L. The objective of this study is to describe real-world patient characteristics and clinical effectiveness associated with P+L as initial endocrine-based therapy use 4 years post approval.
Methods
Adult postmenopausal women diagnosed with metastatic HR+/HER2- breast cancer who initiated P+L as first-line therapy on or after 2/3/2015 were identified by providers in the Cardinal Health Oncology Provider Extended Network, including 1800 oncologists/hematologists in the US. A subset of providers abstracted data related to patient characteristics and clinical outcomes including disease response and disease progression into an electronic case report from (eCRF). Data were abstracted from the time of initiation of P+L through Feb 2019 (or end of follow up/death). Providers were shown response classification schema corresponding to RECIST v1.1 and asked to indicate the patient’s best response if recorded. The objective response rates (ORR – incl. complete response [CR] and partial response [PR]), clinical benefit rates (CBR – incl. CR+PR+stable disease [SD] >24 wks), and progression-free survival (PFS) rate at 12-month were reported. Each eCRF was reviewed by independent clinical staff; source data was verified on 10% of the patients.
Results
31 providers submitted 202 eCRFs, of which, 193 were eligible. Median follow-up from 1L P+L initiation was 15.4 months, 45.6% of patients had discontinued P+L at data cut-off. Table shows key patient characteristics and ORR, CBR, and PFS rate at 12-month, each showing benefit of 1L P+L in the real-world.Table:
338P
N = 193 | All |
---|---|
Mean age at diagnosis, yrs | 62.7 |
Non-Hispanic white, % | 74.6 |
Black/African-American, % | 17.1 |
ECOG-PS 0/1, % | 89.6 |
N0, % | 22.8 |
Visceral mets, % | 51.3 |
Bone only mets, % | 25.4 |
ORR, % | 65.8 |
CR | 9.8 |
PR | 56.0 |
CBR†, % | 88.0 |
CR | 12.7 |
PR | 61.3 |
SD† | 14.0 |
12-month PFS, % | 74.5 |
†Excluding 43 patients with duration of treatment <24 wks
Conclusions
These real-world data demonstrate the benefit of 1L P+L 4 years post approval in the US and support the clinical benefit of 1L P+L reported in randomized clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pfizer Inc.
Funding
Pfizer Inc.
Disclosure
J. Kish: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. J. Trocio: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. T. Miller: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. D. Nero: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. D. Liassou: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. X. Liu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. L. McRoy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. B. Feinberg: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc.
Resources from the same session
3716 - Prognostic factors for predicting early recurrence within the first year of surgery in pancreatic ductal adenocarcinoma
Presenter: Naru Kim
Session: Poster Display session 2
Resources:
Abstract
3947 - Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)
Presenter: Teresa Macarulla
Session: Poster Display session 2
Resources:
Abstract
2880 - Expression of long noncoding RNA and clinical outcomes of pancreatic cancer patients who received adjuvant chemotherapy by S-1 or GEM after curative resection.
Presenter: Mariko Kamiya
Session: Poster Display session 2
Resources:
Abstract
5029 - POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract
4730 - Diagnostic Value of Digital Multiplexed Detection of Single Nucleotide Variants in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasound Fine-Needle Aspiration
Presenter: Irina Cazacu
Session: Poster Display session 2
Resources:
Abstract
3303 - Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
Presenter: Esther Pijnappel
Session: Poster Display session 2
Resources:
Abstract
2009 - Efficacy of platinum-containing chemotherapy and prognosis of pancreatic cancer patients with homologous recombination deficiency: meta-analysis of published clinical studies
Presenter: Elizeveta Polyanskaya
Session: Poster Display session 2
Resources:
Abstract
2164 - Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients
Presenter: Valeria Merz
Session: Poster Display session 2
Resources:
Abstract
2529 - A protein level signature of four selected genes associated with survival outcomes of patients with pancreatic ductal adenocarcinoma
Presenter: Jie Hua
Session: Poster Display session 2
Resources:
Abstract
4947 - Pre-treatment serum 25-hydroxyvitamin D levels and survival in a Danish cohort of patients with pancreatic cancer
Presenter: Louise Rasmussen
Session: Poster Display session 2
Resources:
Abstract